Bank of New York Mellon Corp Invests $62.79 Million in Halozyme Therapeutics, Inc. $HALO

Bank of New York Mellon Corp purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, Holdings Channel reports. The institutional investor purchased 802,245 shares of the biopharmaceutical company’s stock, valued at approximately $62,792,000.

Other hedge funds also recently modified their holdings of the company. Measured Wealth Private Client Group LLC increased its holdings in Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 124 shares in the last quarter. Larson Financial Group LLC raised its position in Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 343 shares during the last quarter. Harbour Investments Inc. boosted its stake in shares of Halozyme Therapeutics by 152.5% during the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 372 shares in the last quarter. Clearstead Advisors LLC boosted its stake in shares of Halozyme Therapeutics by 64.8% during the fourth quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 331 shares in the last quarter. Finally, Wexford Capital LP bought a new stake in shares of Halozyme Therapeutics during the third quarter worth about $70,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on HALO shares. Weiss Ratings downgraded Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, August 14th. Morgan Stanley reduced their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and upped their price target for the company from $83.00 to $110.00 in a research report on Friday, August 7th. UBS Group reaffirmed a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Finally, TD Cowen lifted their price target on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $91.20.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $107.06 on Thursday. The stock’s 50 day moving average is $85.50 and its 200 day moving average is $74.39. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $109.66. The firm has a market cap of $12.15 billion, a P/E ratio of 31.96, a P/E/G ratio of 0.44 and a beta of 0.85. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the prior year, the firm posted $1.54 EPS. The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at $79,987,320.40. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the transaction, the director directly owned 40,418 shares of the company’s stock, valued at $4,154,970.40. This represents a 3.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 64,103 shares of company stock worth $5,226,496 over the last three months. 2.50% of the stock is owned by company insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.